New drug showdown: can secukinumab outperform ustekinumab for tough psoriatic arthritis?
NCT ID NCT04632927
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tested two injectable drugs, secukinumab and ustekinumab, in 119 adults with active psoriatic arthritis who had not responded to or could not tolerate TNFα inhibitors. The main goal was to see which drug better improved physical function over 28 weeks. Both drugs aim to control disease activity, but patients may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Rendsburg, Schleswig-Holstein, 24768, Germany
-
Novartis Investigative Site
Aachen, 52074, Germany
-
Novartis Investigative Site
Bad Bentheim, 48455, Germany
-
Novartis Investigative Site
Bad Doberan, 18209, Germany
-
Novartis Investigative Site
Berlin, 12435, Germany
-
Novartis Investigative Site
Berlin, 13125, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Bochum, 44791, Germany
-
Novartis Investigative Site
Cologne, 50937, Germany
-
Novartis Investigative Site
Cologne, 51149, Germany
-
Novartis Investigative Site
Cottbus, 03042, Germany
-
Novartis Investigative Site
Dresden, 01067, Germany
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Ehringshausen, 35630, Germany
-
Novartis Investigative Site
Erlangen, 91056, Germany
-
Novartis Investigative Site
Frankfurt, 60590, Germany
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Gommern, 39245, Germany
-
Novartis Investigative Site
Göttingen, 37075, Germany
-
Novartis Investigative Site
Hamburg, 22391, Germany
-
Novartis Investigative Site
Herne, 44649, Germany
-
Novartis Investigative Site
Leipzig, 04103, Germany
-
Novartis Investigative Site
Magdeburg, 39104, Germany
-
Novartis Investigative Site
Magdeburg, 39110, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
München, 81541, Germany
-
Novartis Investigative Site
Planegg, 82152, Germany
-
Novartis Investigative Site
Ratingen, 40878, Germany
Conditions
Explore the condition pages connected to this study.